Genetics of Bladder Malignant Tumors in Childhood
Authors:
Open Access
- 27 October 2015
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Genomics
- Vol. 17 (1) , 14-32
Abstract
Bladder masses are represented by either benign or malignant entities. Malignant bladder tumors are frequent causes of disease and death in western countries. However, in children they are less common. Additionally, different features are found in childhood, in which non epithelial tumors are more common than epithelial ones. Rhabdomyosarcoma is the most common pediatric bladder tumor, but many other types of lesions may be found, such as malignant rhabdoid tumor (MRT), inflammatory myofibroblastic tumor and neuroblastoma. Other rarer tumors described in literature include urothelial carcinoma and other epithelial neoplasms. Rhabdomyosarcoma is associated to a variety of genetic syndromes and many genes are involved in tumor development. PAX3-FKHR and PAX7-FKHR (P-F) fusion state has important implications in the pathogenesis and biology of RMS, and different genes alterations are involved in the pathogenesis of P-F negative and embryonal RMS, which are the subsets of tumors most frequently affecting the bladder. These genes include p53, MEF2, MYOG, Ptch1, Gli1, Gli3, Myf5, MyoD1, NF1, NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, IGF1R, PDGFRA, ERBB2/4, MET, BCOR. Malignant rhabdoid tumor (MRT) usually shows SMARCB1/INI1 alterations. Anaplastic lymphoma kinase (ALK) gene translocations are the most frequently associated alterations in inflammatory myofibroblastic tumor (IMT). Few genes alterations in urothelial neoplasms have been reported in the paediatric population, which are mainly related to deletion of p16/lnk4, overexpression of CK20 and overexpression of p53. Here, we reviewed available literature to identify genes associated to bladder malignancies in children and discussed their possible relationships with these tumors.Keywords
This publication has 154 references indexed in Scilit:
- Effects of RAS on the genesis of embryonal rhabdomyosarcomaGenes & Development, 2007
- Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genesJournal of Clinical Investigation, 2006
- The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activationOncogene, 2006
- Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutationsJournal of Medical Genetics, 2006
- Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome PhenotypeThe American Journal of Human Genetics, 2006
- Two neurofibromatosis type 1 cases associated with rhabdomyosarcoma of bladder, one with a large deletion in the NF1 geneCancer Genetics and Cytogenetics, 2006
- Germline mutations in HRAS proto-oncogene cause Costello syndromeNature Genetics, 2005
- Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane MicrolocalizationJournal of Biological Chemistry, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?British Journal of Cancer, 2001